Key facts
- Westinghouse Electric Company has confidentially filed for a U.S. IPO.
- Westinghouse supplies nuclear technology and services.
- The nuclear sector is seeking to tap capital markets.
- Rising U.S. power demand is a factor for the nuclear sector.
- Braveheart Bio is a clinical-stage biopharmaceutical company.
- Braveheart Bio is targeting a valuation of up to $1.2 billion for its U.S. IPO.
- Braveheart Bio aims to raise $318.8 million.
- Braveheart Bio will offer 18.8 million shares.
- Braveheart Bio's shares are priced between $15 and $17 each.
Westinghouse Electric Company, a key supplier of nuclear technology and services, has confidentially filed for an initial public offering (IPO) in the United States. This strategic move by the company, and others within the nuclear sector, is driven by a desire to access capital markets as U.S. power demand continues to rise. The filing indicates Westinghouse's intention to leverage public investment to support its operations and growth.